Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a daily pill tame hepatitis d?

NCT ID NCT07762027

Not yet recruiting Disease control Sponsor: Assembly Biosciences Source: ClinicalTrials.gov ↗

First seen Aug 13, 2026 · Last updated Aug 14, 2026 · Updated 1 time

Summary

This Phase 2 trial is testing an experimental oral drug called ABI-6250 in about 80 people with chronic hepatitis D, a serious liver infection. Participants take the pill once daily for 48 weeks. The study aims to see if the drug is safe, how it moves through the body, and whether it can lower hepatitis D virus levels and improve liver function.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
ABI-6250, an oral tablet taken once daily for 48 weeks
What this could lead to
If successful, this could lead to a new oral treatment option for chronic hepatitis D, potentially reducing viral levels and improving liver health.
What could go wrong
This is an early-stage trial with a small number of participants, so results may not be conclusive. The drug may cause side effects or may not effectively control the infection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS D INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatitis D virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC HEPATITIS D INFECTION

Contacts and locations

Locations

  • AP-HP - Beaujon Hospital

    Clichy, France

  • ARENSIA Exploratory Medicine Ivano-Frankivsk

    Ivano-Frankivsk, Ukraine

  • Aga Khan University Hospital

    Karachi, Pakistan

  • Arensia Research Clinic

    Bucharest, Romania

  • Azienda Ospedaliera Universitaria

    Naples, Italy

  • CHU Lyon - Hôpital Croix-Rousse

    Lyon, France

  • Clinical Republican Hospital

    Chisinau, Moldova

  • Dr. Victor Babes Foundation

    Bucharest, Romania

  • Dr. Ziauddin Hospital

    Karachi, Pakistan

  • Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico

    Milan, Italy

  • Fundeni Clinical Institute

    Bucharest, Romania

  • Hospital Clínico Universitario Lozano Blesa

    Zaragoza, Spain

  • Hôpital Henri-Mondor

    Créteil, France

  • King's College Hospital London

    London, United Kingdom

  • LLC Neolab

    Tbilisi, Georgia

  • Medical Center of LLC ARENSIA Exploratory Medicine

    Kyiv, Ukraine

  • Medizinische Hochschule Hannover

    Hanover, Germany

  • New Zealand Clinical Research

    Auckland, New Zealand

  • North Manchester General Hospital

    Manchester, United Kingdom

  • Prof. Dr. Matei Bals National Institute of Infectious Diseases

    Bucharest, Romania

  • The Royal London Hospital

    London, United Kingdom

  • Universitätsklinikum Hamburg-Eppendorf

    Hamburg, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.